Work

Vesiculobullous eruption with loncastuximab tesirine in a patient with relapsed follicular lymphoma

Year: 2024

Type: article

Abstract: Loncastuximab tesirine (LT) is an antibody-drug conjugate (ADC) that has shown efficacy in patients with relapsed/refractory B-cell malignancies.1,2 It comprises an anti-cluster of differentiation (CD)19 antibody linked to the pyrrolobenzodiazepine dimer SG3199, a potent inter-strand minor-groove DNA crosslinking agent, and has prolonged cytotoxic activity against CD19+ cells.3 Cutaneous toxicities to LT are limited due to its specificity and short half-life, with reactions including a nonspecific maculopapular or pustular rash, photosensitivity, and ulcers.

Source: JAAD Case Reports

DOI: 10.1016/j.jdcr.2024.08.013

Authors: Riyad N.H. Seervai, Craig Y. Okada, Stephanie J. Mengden-Koon, Noah I. Hornick

Institution: Oregon Health & Science University

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750